Skip to content
japan-header

JAPAN

Aspen Japan operates according to a flexible business model and employs innovative marketing activities to promote leading international pharmaceutical originator brands and authorised generics in Japan.

Contribution to Group revenue (%)

pic-13europe

Revenue by segment (%)

pic-14europe
  • The Japanese pharmaceutical sector continues to be negatively impacted by regulated price revisions and was valued at USD76 billion as at 31 December 2018

Source: December 2018 IQVIA

STATISTICS

Number of products launched:

4

(2018: 9)#

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:

0 – 2 years

Nil

3 – 5 years

Nil

Number of product recalls:

Nil

(2018: Nil)

Average staff turnover:

13,9%

(2018: 12,8%)

Number of work-related fatalities:

Nil

(2018: Nil)

Number of permanent employees:

june-07

# The number of product launches has been restated to take into account discontinued operations.

Revenue2019
R'million
2018 (CER)
R'million
change
%
Regional Brands7607353
Sterile Focus Brands1 3641 384(1)
   Anaesthetics Brands1 3321 3310
   Thrombosis Brands3253(40)
Total2 1242 119 0

Note: Commercial Pharmaceuticals revenue is disclosed by customer geography.

Scroll To Top